PEs are going to see healthy growth in life sciences: K V Ramakrishna

We believe there are several interesting opportunities at the growth stage, across biopharma, says Ramakrishna

Almost a decade after it raised its first life sciences fund, Kotak Private Equity Group is in the process of raising the second one. K V Ramakrishna, chief executive officer, to Sohini Das. Edited excerpts:

What is the size of the fund?

The target is Rs 5 billion, with a greenshoe (over-allotment) option of Rs 5 billion.

What returns do you expect?

In line with past experience, we expect  over 20 per cent IRR (internal rate of return) from individual investments.

What returns did you get in your first life sciences fund?

Realised returns are over 27 per cent IRR.